Tag - VIV

Feature

Avivagen’s OxC-beta as natural alternative to antibiotics

By Len Zehr Three peer-reviewed research papers published this year by Avivagen (TSX-V:VIV) and independent collaborators, backed up with successful testing in Asia, have put the company in a position to pursue major...

December 9, 2014

Feature

Avivagen shifts to commercial mindset from R&D

By Len Zehr Cameron Groome, who moved into the executive suite at Avivagen (TSX-V:VIV) in March, has transformed the focus of the animal wellness company to a business and product development engine and away from an...

June 18, 2013

Tag - VIV

Avivagen’s OxC-beta as natural alternative to antibiotics

Avivagen shifts to commercial mindset from R&D

General

More